Real World Study on Erlotinib/Gefitinib Combined With Bevacizumab in Advanced Non-aquamous Non-small Cell Lung Cancer

Last updated: December 25, 2023
Sponsor: Hunan Province Tumor Hospital
Overall Status: Active - Recruiting

Phase

N/A

Condition

N/A

Treatment

Erlotinib/Gefitinib combined with Bevacizumab

Clinical Study ID

NCT03647592
WECAN
  • Ages 18-80
  • All Genders

Study Summary

This study aims to explore the efficacy and safety of Erlotinib/Gefitinib combined with bevacizumab in the real world for advanced non-squamous cell lung cancer with EGFR mutation, explore new drug resistance mechanisms under the A+T regimen and consistency between plasma and tissue detection driving genes, and finally assess the predictive value of plasma dynamic detection driving gene mutation profiles in predicting disease. The role of disease progression risk.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • EGFR mutation(19del/L858R)
  • advanced non-saquamous non-small cell lung cancer
  • primary treatment of first diagnosis
  • performance status（0-1)

Exclusion

Exclusion Criteria:

  • other genes mutation
  • saquamous

Study Design

Total Participants: 30
Treatment Group(s): 1
Primary Treatment: Erlotinib/Gefitinib combined with Bevacizumab
Phase:
Study Start date:
June 01, 2018
Estimated Completion Date:
December 01, 2025

Study Description

A retrospective study of 30 cases of advanced non-squamous non-small cell lung cancer (NSCLC) with EGFR mutation positive treated with A+T was conducted to observe the efficacy and safety of A+T regimen in the real world. Exploratory research contents are as follows: 1. Consistency between tissue gene test (NGS) and plasma gene test (NGS) at the initial diagnosis; 2. Consistency between tissue gene test (NGS) and plasma gene test (NGS) at the progression of A + T treatment; 3. New drug resistance mechanism of A + T treatment; 4. Plasma dynamics during A + T treatment. Detection (the first efficacy evaluation and a blood sampling before imaging PD) exploration and imaging progress sequence; 5. Plasma large panel dynamic drive gene mutation spectrum analysis to build disease progression risk model.

Connect with a study center

  • Hunan Provincal Tumor Hospital

    Changsha, Hunan 410013
    China

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.